{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01283139: Phase 2 Interventional Completed Systemic Lupus Erythematosus
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02174276: Phase 2 Interventional Completed Chronic Hepatitis B
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02725411: Phase 3 Interventional Completed Low Back Pain
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01123083: Phase 3 Interventional Completed Diabetes Mellitus, Type 1
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03275103: Phase 1 Interventional Active, not recruiting Multiple Myeloma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03932110: Not Applicable Interventional Completed Psoriasis Vulgaris
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:eblasakimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:trastuzumab rezetecan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:zelenectide pevedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03607838: Phase 3 Interventional Completed Lumbar Disc Herniation
(2018)
Source URL:
Class:
PROTEIN
